STATEMENT OF NEED/TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and patient care, this program features one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the clinical implications of research data on breast cancer treatment, and apply this information to management strategies in the adjuvant and metastatic settings.
• Select adjuvant chemotherapy (anthracycline- versus nonanthracycline-containing regimens), hormonal therapy and/or biologic therapy with trastuzumab, based on risk-benefit analyses and individual patient characteristics.
• Incorporate emerging data on biologic therapies into treatment algorithms for appropriately selected patients with metastatic breast cancer.
• Assess the contributory roles of hormone receptor and HER2 status on treatment selection and sequencing for metastatic breast cancer, and apply this information to patient care.
• Review the evidence on the evolving role of lifestyle modifications and their impact on the risk of breast cancer recurrence, and discuss this information with patients.
• Counsel appropriately selected patients about ongoing clinical trials in which they may wish to participate.

PURPOSE OF THIS ISSUE

The purpose of this program is to support the learning objectives by offering the perspectives of Drs Chlebowski, O’Shaughnessy, Pegram, Slamon, Sledge, Swain and Winer on the integration of emerging clinical research data into the management of breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Evaluation Form located at www.BreastCancerUpdate.com/CME. www.BreastCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

---

This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.

Home | Search

TOPICS

Adjuvant Chemotherapy for Patients with HER2-Negative Disease

Adjuvant Systemic Therapy for Patients with HER2-Positive Disease

Adjuvant Therapy for Elderly Patients with HER2-Positive Disease

Adjuvant Trial Evaluating Trastuzumab and/or Lapatinib in HER2-Positive Disease
- Select publications

Role of Bevacizumab for Patients with HER2-Negative Metastatic Disease

Adjuvant Trial Combining Bevacizumab with Trastuzumab

Optimizing First-Line Systemic Therapy for Patients with ER-Positive, HER2-Positive Metastatic Disease
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office